cp wire

CP Wire Articles

Teva to Discontinue Trial of Fremanezumab in Chronic Cluster Headache

  • Futility analysis found primary endpoint... read more

Fri, 06/15/18 - 08:54 am
Trillium Therapeutics Doses First Patient With Checkpoint Inhibitor TTI-622

Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL) announced on 6/14/2018 that it has initiated dosing in its phase 1 clinical trial of TTI-622 (SIRPaFc-IgG4), a checkpoint inhibitor of the... read more

Thu, 06/14/18 - 10:07 am
Pharnext's PXT3003 Granted Priority Review by China Food and Drug Administration for Neurodegenerative Disease
  • PXT3003 is in Ph III in the US and Europe
  • Granted orphan status in US and Europe
  • CMT is one of the most common inherited neurological disorders

Pharnext SA (... read more

Thu, 06/14/18 - 09:51 am
Verseon to Initiate Ph I Study of New Class Anticoagulant with Reduced Bleeding Risk

Verseon will be starting a first-in-human phase I trial in Australia for its lead-PROAC (PRecision Oral AntiCoagulant) VE-1902, which has successfully completed regulatory toxicology studies and... read more

Thu, 06/14/18 - 09:31 am
Johnson & Johnson’s Tremfya Approved for Reimbursement in the UK and Germany

Johnson & Johnson announced on 6/13/2018 that the United Kingdom’s National Institute for Health and Care Excellence (NICE) has published positive guidance for Tremfya® (guselkumab), following... read more

Wed, 06/13/18 - 10:25 am

Pages